Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.86 |
| ▸ | HTT | P42858 | 8/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.86 |
| ▸ | LMNA | P02545 | 7/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.86 |
| ▸ | MEN1 | O00255 | 5/20 | 0.86 |
| ▸ | NPC1 | O15118 | 4/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.64 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683795 | 1.00 | MAPT (0.86) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL28295711 | 0.99 | MAPT (0.84) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL28800601 | 0.95 | MAPT (0.82) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL29741767 | 0.94 | MAPT (0.77) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL16035430 | 0.91 | MAPT (0.80) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL19283293 | 0.91 | MAPT (0.80) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL14907041 | 0.91 | MAPT (0.80) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL29741703 | 0.90 | MAPT (0.74) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL29741716 | 0.90 | MAPT (0.74) | MAPTKDM4EHTTSMN1; SMN2LMNA | |
| SCHEMBL14949043 | 0.90 | MAPT (0.78) | MAPTKDM4EHTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685536-B | Binuclear cadmium complex with anticancer activity and preparation method and application thereof | 中山职业技术学院 | 2022-09-02 | — | — | CN | claimed |
| CN-109705167-B | Preparation and application of two nickel acylhydrazone Schiff base complexes | 南京林业大学 | 2021-06-11 | — | — | CN | claimed |
| EP-3515427-A2 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | Qingdao Primedicine Pharmaceutical Co., Ltd (CN) | 2019-07-31 | — | — | EP | claimed |
| CN-114685536-B | Binuclear cadmium complex with anticancer activity and preparation method and application thereof | 中山职业技术学院 | 2022-09-02 | — | — | CN | disclosed |
| CN-114685536-A | Binuclear cadmium complex with anticancer activity and preparation method and application thereof | 中山职业技术学院 | 2022-07-01 | — | — | CN | disclosed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| CN-109705167-B | Preparation and application of two nickel acylhydrazone Schiff base complexes | 南京林业大学 | 2021-06-11 | — | — | CN | disclosed |
| CN-109705167-B | Preparation and application of two nickel acylhydrazone Schiff base complexes | 南京林业大学 | 2021-06-11 | — | — | CN | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| US-20090275070-A1 | Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators | HOUSEY GERARD M | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | GRIN2A, GRIN3A, GRIN1 | MAPT 695/4885KDM4E 1424/4885HTT 337/4885 |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | GRIN2A, GRIN3A, GRIN1 | MAPT 695/4885KDM4E 1424/4885HTT 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.